E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Severe aortic stenosis |
Estenosis aórtica severa |
|
E.1.1.1 | Medical condition in easily understood language |
Severe aortic stenosis |
Estenosis aórtica severa |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cardiovascular Diseases [C14] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10002906 |
E.1.2 | Term | Aortic stenosis |
E.1.2 | System Organ Class | 10047065 - Vascular disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To perform a 1: 1 randomized study in patients who underwent a percutaneous aortic prosthesis as treatment for severe degenerative aortic stenosis and to compare the cardiovascular events, in a follow-up of 3 years, including death from cardiac cause, admission for heart failure and stroke, in patients who have received standard treatment plus ramipril versus patients who have received the usual treatment |
Realizar un estudio aleatorizado 1:1, abierto en pacientes a los que se ha puesto una prótesis percutánea aórtica como tratamiento de la estenosis aórtica degenerativa severa y comparar los eventos cardiovasculares, que incluye muerte de causa cardíaca, ingreso por insuficiencia cardíaca e ictus, en un seguimiento de 3 años, en pacientes que han recibido tratamiento habitual más ramipril frente a pacientes que han recibido el tratamiento habitual. |
|
E.2.2 | Secondary objectives of the trial |
As part of the hypothesis of study, the randomized trial will compare the evolution of left ventricular remodeling at the year of follow-up, between the active treatment group and the control group. Specifically, we will evaluate: Ventricular mass, myocardial fibrosis, ventricular dimensions and ejection fraction.
In addition, other aspects will be compared between the two groups:
1) Functional capacity at one-year follow-up
2) Cardiac cause of death (if the cause of death is unknown, it will be considered of cardiac cause) at one year and at three years of follow-up.
3) Revenue from heart failure at one year and at three years of follow-up.
4) Stroke (compatible symptoms and demonstration with imaging technique) at one year and at three years of follow-up.
5) Death of any cause at one year and at three years of follow-up.
|
Como parte de la hipótesis de estudio, en el ensayo aleatorizado se comparará la evolución del remodelado ventricular izquierdo al año de seguimiento entre el grupo de tratamiento activo y el grupo control. Concretamente se evaluarán: Masa ventricular, fibrosis miocárdica, dimensiones ventriculares y fracción de eyección.
Además, se compararán otros aspectos entre el grupo de tratamiento activo y el grupo control:
1) Capacidad funcional al año de seguimiento
2) Muerte de causa cardíaca (si la causa de muerte no se conoce se considerará de causa cardíaca) al año y a los tres años del seguimiento.
3) Ingreso por insuficiencia cardíaca al año y a los tres años del seguimiento.
4) Ictus (síntomas compatibles y demostración con técnica de imagen) al año y a los tres años del seguimiento.
5) Muerte de cualquier causa al año y a los tres años. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
- Replacement of the aortic valve with a percutaneous prosthesis decided by the heart team due to severe aortic stenosis.
- Do not have any device not compatible with RM.
- Ability to understand and sign informed consent.
- They do not meet any of the exclusion criteria.
|
Se incluirán en el estudio, pacientes mayores de 60 años de edad, reclutados en el área de hospitalización, que cumplan los siguientes requisitos: diagnóstico de estenosis aórtica severa por criterios ecocardiográficos.
CRITERIOS DE INCLUSIÓN
- Sustitución de la válvula aórtica con una prótesis percutánea aceptada en una sesión médico-quirúrgica por estenosis aórtica severa.
- No tienen ningún dispositivo no compatible con RM.
- Capacidad de entender y firmar el consentimiento informado.
- No cumplen ninguno de los criterios de exclusión. |
|
E.4 | Principal exclusion criteria |
- Associated mitral valvulopathy requiring intervention.
- Left ventricular ejection fraction <40% and to have history of myocardial infarction or previous diagnosis of dilated cardiomyopathy.
- Prescription of SRA blockers in the 3 months prior to the start of the study.
- Known allergy or intolerance to IECAs.
- Severe chronic kidney disease (glomerular filtration <30 ml / min). Patients between 30 and 50 ml / min, will participate in the study but they will not be given gadolinium during MRI.
- Systolic arterial pressure less than 100 mmHg or diastolic less than 40 mmHg.
- Pregnancy in second or third trimester.
- Participation in another clinical trial.
|
CRITERIOS DE EXCLUSIÓN
- Valvulopatía mitral asociada que requiera intervención.
- Fracción de eyección ventricular izquierda menor del 40% y antecedentes de infarto de miocardio o diagnóstico previo de miocardiopatía dilatada.
- Prescripción de bloqueantes del SRA en los 3 meses previos al comienzo del
estudio.
- Alergia o intolerancia conocida a los IECAs.
- Insuficiencia renal significativa (filtrado glomerular < 30 ml/min). Si está entre 30 y 50 ml/min, puede entrar en el estudio pero no se le administrará gadolinio durante la RM.
- Presión sistólica menor de 100 mmHg o diastólica menor de 40 mmHg.
- Embarazo en segundo o tercer trimestre.
- Participación en otro ensayo clínico. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Cardiovascular events, including death from cardiac cause, admission for heart failure and stroke |
Eventos cardiovasculares que incluye muerte de causa cardíaca, ingreso por insuficiencia cardíaca e ictus. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
At the first year and at a follow-up of 3 years |
Al año y en un seguimiento de 3 años. |
|
E.5.2 | Secondary end point(s) |
Left ventricular remodeling. Specifically: Ventricular mass, myocardial fibrosis, ventricular dimensions and ejection fraction. |
Remodelado ventricular izquierdo. Concretamente: masa ventricular, fibrosis miocárdica, dimensiones ventriculares y fracción de eyección. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
At the first year and at a follow-up of 3 years |
Al año y en un seguimiento de 3 años. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 5 |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 5 |
E.8.9.2 | In all countries concerned by the trial months | 6 |